Research in the field of complex coding in cancer is rapidly advancing, driven by technologies such as next-generation sequencing and CRISPR-based gene editing. These tools allow for comprehensive analysis of cancer genomes and the identification of novel targets for therapy. Ongoing clinical trials are exploring the efficacy of new drugs targeting specific genetic and molecular alterations in cancer.
